{"id":"fluticasone-salmeterol-tiotropium","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Hoarseness"},{"rate":null,"effect":"Dry mouth"}]},"_chembl":{"chemblId":"CHEMBL1676","moleculeType":"Small molecule","molecularWeight":"538.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate is an inhaled corticosteroid that suppresses airway inflammation by binding glucocorticoid receptors. Salmeterol is a long-acting beta-2 agonist that activates beta-2 adrenergic receptors on airway smooth muscle to cause bronchodilation. Tiotropium is a long-acting muscarinic antagonist (anticholinergic) that blocks M3 receptors on airway smooth muscle, providing additional sustained bronchodilation and reducing mucus secretion.","oneSentence":"This combination inhaler delivers a corticosteroid (fluticasone) to reduce airway inflammation and a long-acting beta-2 agonist (salmeterol) to dilate airways, plus a long-acting muscarinic antagonist (tiotropium) for sustained bronchodilation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:46:44.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma (maintenance therapy)"}]},"trialDetails":[{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT05179512","phase":"","title":"Replication of the INSPIRE Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":98278},{"nctId":"NCT05748977","phase":"EARLY_PHASE1","title":"Short Acting Agents Vs Long Acting in Frequent Excerbator COPD Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-02-20","conditions":"Copd","enrollment":80},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT03158311","phase":"PHASE3","title":"Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-02-05","conditions":"Asthma","enrollment":1426},{"nctId":"NCT04179461","phase":"PHASE2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-03-16","conditions":"Asthma in Children","enrollment":21},{"nctId":"NCT03219866","phase":"PHASE4","title":"Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-03","conditions":"COPD, COPD Exacerbation","enrollment":40},{"nctId":"NCT03395002","phase":"PHASE4","title":"Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2018-03-22","conditions":"COPD","enrollment":58},{"nctId":"NCT03240575","phase":"PHASE4","title":"The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-08-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":302},{"nctId":"NCT04208581","phase":"PHASE3","title":"Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2019-10-08","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Respiratory Failure","enrollment":372},{"nctId":"NCT01794780","phase":"PHASE4","title":"A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-05","conditions":"COPD","enrollment":2229},{"nctId":"NCT03055988","phase":"PHASE4","title":"Cardiovascular Function in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76},{"nctId":"NCT02202616","phase":"PHASE4","title":"Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-08-27","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":401},{"nctId":"NCT02603393","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-20","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1053},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT03745261","phase":"PHASE3","title":"Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2018-06-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":240},{"nctId":"NCT01290874","phase":"PHASE3","title":"Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-03-30","conditions":"Asthma","enrollment":1070},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT01124422","phase":"PHASE4","title":"Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":255},{"nctId":"NCT01331694","phase":"","title":"Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76130},{"nctId":"NCT01332461","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":5677},{"nctId":"NCT01381406","phase":"","title":"Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3333},{"nctId":"NCT00706446","phase":"NA","title":"The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2008-06","conditions":"Asthma","enrollment":255},{"nctId":"NCT01337336","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1},{"nctId":"NCT03169504","phase":"PHASE3","title":"Effect of Acupuncture on Patients With Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2017-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":150},{"nctId":"NCT01381458","phase":"","title":"Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1936},{"nctId":"NCT01387178","phase":"","title":"Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22223},{"nctId":"NCT01395875","phase":"","title":"Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2849},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT01751113","phase":"PHASE4","title":"A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":53},{"nctId":"NCT00857766","phase":"PHASE4","title":"A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":249},{"nctId":"NCT00361959","phase":"PHASE4","title":"SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1270},{"nctId":"NCT02441114","phase":"PHASE1","title":"Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011)","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2015-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":10},{"nctId":"NCT00784550","phase":"PHASE4","title":"A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":342},{"nctId":"NCT01762800","phase":"PHASE4","title":"Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":407},{"nctId":"NCT02790047","phase":"NA","title":"Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2016-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":50},{"nctId":"NCT01969721","phase":"PHASE3","title":"Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":229},{"nctId":"NCT02546349","phase":"PHASE4","title":"Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2014-07","conditions":"COPD","enrollment":143},{"nctId":"NCT00975195","phase":"PHASE4","title":"Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2488},{"nctId":"NCT01513460","phase":"PHASE3","title":"Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":773},{"nctId":"NCT00535366","phase":"PHASE2","title":"Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":103},{"nctId":"NCT00530842","phase":"PHASE4","title":"Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":344},{"nctId":"NCT00239499","phase":"PHASE4","title":"Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":107},{"nctId":"NCT00239421","phase":"PHASE4","title":"A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":605},{"nctId":"NCT00864812","phase":"PHASE4","title":"Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea","status":"COMPLETED","sponsor":"The Korean Academy of Tuberculosis and Respiratory Diseases","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":509},{"nctId":"NCT00668408","phase":"PHASE4","title":"LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2008-05","conditions":"Lung Diseases, Obstructive, Chronic Heart Failure, Chronic Hypoxemia","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["seretide evohaler 250","spiriva respimat"],"phase":"marketed","status":"active","brandName":"fluticasone/salmeterol, tiotropium","genericName":"fluticasone/salmeterol, tiotropium","companyName":"Taipei Veterans General Hospital, Taiwan","companyId":"taipei-veterans-general-hospital-taiwan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhaler delivers a corticosteroid (fluticasone) to reduce airway inflammation and a long-acting beta-2 agonist (salmeterol) to dilate airways, plus a long-acting muscarinic antagonist (tiotropium) for sustained bronchodilation. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}